Management of Alcohol Withdrawal in the ICU

Pharmacologic First‑Line Therapy

• Benzodiazepines are the gold‑standard first‑line agents for alcohol‑withdrawal syndrome (AWS) in the ICU; lorazepam 6–12 mg per day is preferred for critically ill patients because of its intermediate half‑life and lack of active metabolites in hepatic or respiratory failure. 1
• Lorazepam is specifically recommended for ICU patients with severe AWS, advanced age, liver failure, respiratory failure, or other serious medical comorbidities. 1
• Long‑acting benzodiazepines (e.g., chlordiazepoxide 25–100 mg every 4–6 h or diazepam 5–10 mg every 6–8 h) are preferred for seizure prophylaxis in patients without hepatic dysfunction. 1

Benzodiazepine Dosing and Protocols

• Initiate lorazepam at 1–4 mg IV/IM every 4–8 h, titrating to validated severity scores such as CIWA‑Ar or RASS. 1

Alternative Sedation for Non‑Withdrawal Delirium

• In mechanically ventilated ICU patients who develop delirium unrelated to alcohol withdrawal, dexmedetomidine is preferred over benzodiazepines because it reduces delirium duration by roughly 20 % per day. 2, 3
• Benzodiazepines remain mandatory when delirium is directly attributable to alcohol withdrawal. 2, 4

Thiamine Supplementation

• All ICU patients with AWS should receive thiamine 100–300 mg per day intravenously or intramuscularly to prevent Wernicke encephalopathy. 1
• Thiamine must be administered before any glucose‑containing intravenous fluids to avoid precipitating acute thiamine deficiency. 1

Electrolyte Management

• Any electrolyte abnormalities identified on admission should be corrected promptly. 1

Adjunctive Non‑Benzodiazepine Therapies (for refractory severe AWS)

• Carbamazepine 200 mg orally every 6–8 h can be added for seizure prevention when benzodiazepine doses are maximized. 1
• Haloperidol 0.5–5 mg orally every 8–12 h or 2–5 mg intramuscularly may be used for agitation or hallucinations not controlled by benzodiazepines alone. 1

Contraindicated Medications

• Antipsychotics should not be used in patients at risk for torsades de pointes (e.g., baseline QT prolongation, concurrent QT‑prolonging drugs, or prior torsades). 2

Sedation Depth Recommendations

• Deep sedation is associated with prolonged recovery and increased mortality; a light‑sedation target is recommended whenever feasible. 5

Consistency with General ICU Guidelines

• Although many ICU guidelines favor dexmedetomidine for non‑withdrawal delirium, benzodiazepine therapy remains appropriate and necessary for AWS‑related delirium. 2, 3

Guideline Recommendations for Alcohol‑Withdrawal Management

First‑Line Pharmacologic Therapy

• Benzodiazepines are the gold‑standard treatment for alcohol‑withdrawal syndrome (AWS) and receive a strong A1‑level recommendation (Clinical and Molecular Hepatology guideline, 2013) 6.
• Long‑acting benzodiazepines (chlordiazepoxide, diazepam) are preferred for seizure prophylaxis, while lorazepam 6–12 mg/day is advised for patients with liver failure, respiratory failure, or advanced age (Clinical and Molecular Hepatology, 2013) 6, 7.
• The 2018 EASL (European Association for the Study of the Liver) guidelines state that benzodiazepines provide the most robust protection against seizures and delirium tremens (Journal of Hepatology, 2018) 8.

Approved Non‑Benzodiazepine Alternatives

• Carbamazepine is listed as an effective alternative for seizure prevention in AWS (200 mg orally every 6–8 h) by the Korean Association for the Study of the Liver (Clinical and Molecular Hepatology, 2013) 6, 7, 9.

Phenobarbital Dosing Parameters (when benzodiazepines are contraindicated or have failed)

• Weight‑based loading dose: 10–15 mg/kg IV administered over 30 min; for a 70‑kg adult this equals approximately 700–1,050 mg (Pediatrics, 2008) 10.
• Maximum continuous infusion rate: 50–100 mg per hour (Annals of Oncology, 2014) 11, 12, 13.

Safety Monitoring

• Elderly patients receiving phenobarbital should be monitored for paradoxical excitement (Annals of Oncology, 2014) 11, 12.

Essential Adjunctive Therapy

• All patients receiving phenobarbital for AWS must receive thiamine 100–300 mg/day IV or IM before any glucose‑containing fluids to prevent Wernicke encephalopathy (Clinical and Molecular Hepatology, 2013; also cited in 2013 guideline updates) 6, 7, 9, 14.

Drug‑Interaction Precautions

• Flumazenil should be avoided in patients who have received both benzodiazepines and phenobarbital, as it may precipitate seizures (Pediatrics, 2008) 10.